| Autor: |
Aspas Requena, Gaspar, Dumas, Pierre Yves, Rodriguez Veiga, Rebeca, Bertoli, Sarah, Gil, Cristina, Simand, Celestine, Ramos-Ortega, Fernando Jesús, Peterlin, Pierre, Serrano, Josefina, Birsen, Rudy, Bernal Del Castillo, Teresa, Tavernier, Emmanuelle, Tormo, Mar, Carre, Martin, Garcia, Maria Jose, Contejean, Adrien, Riaza Grau, Rosalia, Orvain, Corentin, Pérez-Simón, Jose Antonio, Perez Santaolla, Esther, Veronese, Lauren, De Rueda Ciller, Beatriz, Delabesse, Eric, Gutiérrez, Antonio, Mineur, Ariane, De La Fuente Burguera, Adolfo, Guieze, Romain, Pigneux, Arnaud, Montesinos, Pau, Recher, Christian, Matínez-Cuadrón, David |
| Zdroj: |
Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p2864-2864, 1p |
| Abstrakt: |
BACKGROUND:The prognosis of patients with acute myeloid leukemia (AML) varies depending on the presence of mutations in the FLT3 tyrosine kinase. Internal tandem duplications (ITD) and mutations in the tyrosine kinase domain (TKD) result in continuous activation of FLT3, leading to uncontrolled blast proliferation. Since the publication of the clinical trial CALGB 10603 (RATIFY), it has been established that adding midostaurine to intensive chemotherapy improves the overall survival (OS) of patients with mutated FLT3. However, it is worth noting that this study only included patients 18-59 years old. Subsequently, a phase II clinical trial (AMLSG 16-10 trial) conducted a subgroup analysis suggesting that midostaurine may also benefit to patients between 60 and 70 years of age. Nevertheless, these findings have not been studied in real-world clinical practice. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
